Twelve law firms will guide the market debuts of at least eight companies during the week of Sept. 28, steering a notable lineup that includes two venture-backed technology businesses opting for direct listings instead of traditional initial public offerings.
Two more Democratic lawmakers Friday joined a growing list of politicians calling to investigate U.S. Department of Defense spending, following reports that the department redirected most of a $1 billion CARES Act appropriation meant to respond to the COVID-19 pandemic to non-emergency contractors instead.
A Principia Biopharma investor filed suit Friday in Delaware Chancery Court for access to records on the company's pending $3.7 billion sale to Sanofi, saying he wants to investigate whether the transaction was fueled by "selfish desires" of certain Principia directors.
Health supplement maker ViSalus is arguing that a lack of uniformity in the types of calls consumers received and whether they consented to this contact should prompt an Oregon federal judge to order a new trial in a long-running robocall dispute, while the lead plaintiff wants to start distributing the $925 million awarded after the original jury trial to class members.
Lawsuits alleging Johnson & Johnson's pharmaceutical unit concealed a harmful side effect of bladder cyst medicine Elmiron should be heard in New Jersey federal court due to the number of cases already filed there, a group of patients told the Judicial Panel on Multidistrict Litigation Friday.
A Massachusetts law firm was sued by the commonwealth, accusing it of accepting more than $90,000 in kickbacks in exchange for referring clients to a mail-order pharmacy that dispensed thousands of opioid prescriptions.
The Minority Corporate Counsel Association announced Friday that American biotech company Genentech, which is part of the multinational Roche Group, is its 2020 Employer of Choice, citing the company's use of data to hold leaders accountable for meeting diversity and inclusion goals.
A Massachusetts federal judge on Friday tossed a proposed class action that alleged home care referral website Care.com and its executives led investors to believe it did background checks on care providers, ruling the company didn't say it would vet every caregiver on its website.
A Merck & Co. unit has asked the U.S. Supreme Court to answer key questions related to whether a hepatitis C treatment patent is invalid in hopes of reviving a $2.54 billion infringement verdict against Gilead — the largest in the nation's history.
A semiconductor distributor and disease test maker will collectively shell out $900,000 after the federal government contractor watchdog determined they had turned away droves of applicants because of their race, the U.S. Department of Labor said Thursday.
An investor in a $2.6 billion biopharmaceutical company that's making the first federally approved peanut allergy treatment for children alleged that the company left out key financial information in disclosures surrounding its planned sale to Nestle, contending in a New York federal court complaint that the omission makes it impossible for shareholders to properly weigh the deal.
A medical science company said Hiscox Inc. breached its insurance contract by not defending it against a suit from Georgia's attorney general alleging the company made more than $6.4 million from its fraudulent stem cell injection products.
The U.S. Securities and Exchange Commission filed suit in California federal court Friday against a top executive of biotechnology company Arrayit Corp. who it says conned investors into believing the company had developed a COVID-19 test and misled them about the status of financial reports.
An Ohio medical marijuana cultivator has sued a state cannabis regulator for taking no action on its expansion application, saying the agency is "punting" on the issue despite a pronounced shortage of marijuana in the Buckeye State.
A New Jersey state appeals court said Friday that onetime majority shareholders of Cispharma Inc. were still on the hook for more than $250,000 for their successors' costs in a suit alleging the business made defective aspirin.
A Maryland medical marijuana dispensary ignored serial sexual harassment by a former manager and failed to investigate complaints about his lewd comments and inappropriate touching for more than a year, the U.S Equal Employment Opportunity Commission said.
This week in London saw Deutsche Bank sue the Italian city of Naples over derivatives, Nationwide Building Society sue law firm Manches, and institutional investors file two new cases against supermarket chain Tesco. Here, Law360 looks at those and other new claims in the U.K.
The U.S. Food and Drug Administration announced a final rule Thursday that would allow states, tribes, pharmacists and wholesalers to import certain prescription drugs from Canada, following through on an executive order signed by President Donald Trump in July.
President Donald Trump on Thursday delivered a seemingly toothless promise to shield Americans with preexisting conditions, issued an ultimatum on legislation to curb surprise medical billing and unexpectedly announced he's mailing tens of millions of $200 drug discount cards just before the election.
Cannabis company Terrapin is accusing competitor Harmony Foundation of bypassing New Jersey's vetting process to open a medical marijuana dispensary in Hoboken, asking a court to revoke Harmony's application or force the company to be evaluated.
A Massachusetts federal judge on Thursday rejected the federal government's bid to toss Akebia Therapeutics Inc.'s suit challenging the Centers for Medicare & Medicaid Services' exclusion of its kidney disease drug under Medicare Part D for certain uses, saying she would wait for a First Circuit appeal to play out before deciding the suit's fate.
A Nevada dispensary is facing the revocation of its cannabis license and a 10-year ban from the industry after the state's cannabis regulator issued a complaint alleging the company lied to authorities about destroying some of its product.
Johnson & Johnson and Bausch Health US LLC are asking a California federal judge to throw out for the last time claims that they hid the asbestos content of their talc powder products, saying the suit still relies on claims that the judge had previously dismissed with prejudice.
Fertility patients alleging faulty storage tanks made by Chart Industries caused them to lose their genetic material slammed a bid by the company to dismiss their complaint in California federal court as too verbose and confusing, saying the 15-page document is instead clear, concise and to the point.
A Major League Baseball Players Association attorney slammed opposing counsel for an ex-pitcher-turned health supplement salesman in a recently dismissed unfair competition suit against the league and union, telling a California federal judge during a sanctions hearing Thursday that "sometimes lawyers have to say no" to a client's request.
The U.S. Department of Health and Human Services accused Gilead Sciences Inc. on Wednesday of infringing four agency patents covering the use of HIV treatment medication to prevent infection, escalating a fight that has been brewing for months.
The Arizona Supreme Court's recent decision to eliminate prohibitions on nonlawyer ownership of law firms may show that the organized bar's long-standing rhetoric that such rules are essential to protecting the legal profession's core values is overblown, say Anthony Sebok at Cardozo School of Law and Bradley Wendel at Cornell Law School.
President Donald Trump's executive order on international reference pricing for Medicare drugs is likely to either languish in Congress or die in court, but more modest drug pricing reform measures may be viable in the coming year, say attorneys at Ropes & Gray.
Companies engaged in commerce related to COVID-19 or that have received Paycheck Protection Program funding should familiarize themselves with a fraud statute, under which the U.S. Department of Justice has been successful in obtaining injunctions even before defendants are charged with a crime, say attorneys at V&E.
The U.S. Department of Justice's recent letter to the Institute of Electrical and Electronics Engineers, which explicitly supports standard-essential patent owners in their pursuit of injunctive relief and favors a diminished role for antitrust enforcement in intellectual property disputes, bodes well for rebalancing the licensing market, say attorneys at Mintz.
Best practices that can help litigators write convincing discovery motions include thinking about the audience, addressing a few key questions, and leaving out boilerplate from supporting briefs, says Tom Connally at Hogan Lovells.
Congress has multiple means to take the politics out of federal judicial nominations and restore the independence of the U.S. Supreme Court — three of which can be implemented without a constitutional amendment, says Franklin Amanat at DiCello Levitt.
While courts sometimes hold retailers liable for injuries caused by products they sold but did not manufacture — as a California appeals court did recently in Bolger v. Amazon — retailers can implement a number of strategies to reduce product liability litigation risk, say Alexandra Cunningham and Elizabeth Reese at Hunton.
For the last 20 years, at the insistence of both parties, U.S. Supreme Court nominations have been fierce ideological battles — which is bad for the country and bad for the public's perception of the legitimacy of the court, say Judge Eric Moyé, Judge Craig Smith and Winston & Strawn partner Tom Melsheimer.
President Donald Trump's new executive order addressing pricing for drugs covered by Medicare Parts B and D glosses over enormous difficulties in restructuring Medicare operations and is unlikely to lead to any imminent changes, say attorneys at Debevoise.
Recent enforcement actions by federal agencies against businesses making products intended to protect against COVID-19 highlight why companies must understand which regulators they are answerable to, and what standards they must follow when producing, advertising, labeling and selling their goods, say attorneys at Crowell & Moring.
Current privilege logging practices to identify what information is being withheld from discovery often lead to costly disputes, so practitioners should adopt a system based on trust and good faith, similar to the presumptions embedded in the business judgment rule for corporate directors and officers, say Kevin Brady at Volkswagen and Charles Ragan and Ted Hiser at Redgrave.
A little-noticed memo recently issued by the Trump administration in response to the pandemic, directing federal agencies to provide greater due process to individuals and companies under regulatory investigation, represents a long-overdue sea change in the way justice is carried out in enforcement proceedings, say Joan Meyer and Norman Bloch at Thompson Hine.
Financially robust law firms are entering the recruiting market aggressively knowing that dislocations like the COVID-19 crisis present rare competitive opportunities, and firms that remain on the sidelines when it comes to strategic hiring will be especially vulnerable to having their best talent poached, says Brian Burlant at Major Lindsey.
Alliance agreements can help pharmaceutical companies collaborate and resolve patent infringement disputes, especially during these uncertain pandemic times, but may draw questions concerning legitimacy if not properly vetted, say Louis Berneman at Texelerate, and Alan White and Anne Catherine Faye at Analysis Group.
The recent Patent Trial and Appeal Board ruling in Velasco Diez v. McAllister illustrates the problem with a Federal Circuit precedent holding that the board cannot apply its technical expertise as a substitute for expert witnesses, and it offers an invitation to gamesmanship, say Charles Gholz and Daniel Pereira at Oblon McClelland.